Group 1 - The core viewpoint is that actively managed equity funds are regaining attention and performance after years of underperformance, with significant returns observed in 2023 [2][3] - As of August 6, 2023, the Dongcai Ordinary Stock Fund Index and the Mixed Equity Fund Index both exceeded a 16% increase, outperforming passive index funds and fixed-income funds [3] - Nearly 10 actively managed equity funds have doubled their net value this year, with notable funds like Huazhang Medical Industry Selected Mixed Fund seeing a 130% increase in net value [3][4] Group 2 - Despite some actively managed funds experiencing significant inflows, the overall scale of these funds has declined, with a nearly 10 billion yuan drop in total scale in Q2 2023 [4] - The market's rapid changes and sector rotations have increased investment difficulty, with industry rotation cycles shortening to about two months [5][6] - Fund managers are facing higher demands for timely and precise adjustments to their portfolios due to frequent shifts in market sentiment and investment noise [5][6] Group 3 - The investment strategy has shifted from relying on broad market trends to focusing on individual stock selection, with a notable decline in the concentration of holdings in top sectors and stocks [8][9] - Fund managers are increasingly looking for opportunities in smaller, innovative companies, particularly in the pharmaceutical sector, which are on the verge of value reassessment [9][10] - The industry is emphasizing the importance of enhancing research capabilities and establishing a robust investment research framework to adapt to the evolving market landscape [10]